Microscopic Colitis and Risk of Inflammatory Bowel Disease {#sec1}
==========================================================

*A Swedish nationwide study showed an increased risk of inflammatory bowel disease among individuals with microscopic colitis*.

Microscopic colitis is a chronic inflammatory disorder of the large intestine sharing certain genetic predispositions and pathogenic mechanisms with inflammatory bowel disease. In this issue of *Gastroenterology*, Khalili et al used a Swedish nationwide cohort encompassing data on gastrointestinal pathology reports from all pathology departments in Sweden since 1965. A total of 13,957 cases of microscopic colitis were identified between 1990 to 2017 and were matched in a 1:5 ratio to 66,820 population controls. A total of 323 incident cases of ulcerative colitis and 108 cases of Crohn's disease were identified among microscopic colitis patients and 94 ulcerative colitis and 42 Crohn's disease were found in population controls. Microscopic colitis was associated with an adjusted hazard ratio of 17.3 (95% confidence interval \[CI\], 13.7--21.8) for ulcerative colitis and 12.6 (95% CI, 8.8--18.1) for Crohn's disease ([Figure 1](#fig1){ref-type="fig"} ). The 10-year absolute excess risk was 2.6% (95% CI, 2.2--2.9) for ulcerative colitis and 0.9% (95% CI, 0.7--1.1) for Crohn's disease. Although this study lacks data on important lifestyle and environmental risk factors as well as pertinent clinical and endoscopic finding, the study demonstrates increased susceptibility of inflammatory bowel disease among patients with microscopic colitis. Further studies are needed to understand common mechanisms that underlie microscopic colitis and inflammatory bowel disease.Figure 1Increased risk of inflammatory bowel disease among patients with microscopic colitis in a Swedish nationwide cohort

**See** **page 1574**.

COVID-19 in the Eyes of Gastroenterologists {#sec2}
===========================================

*Gastrointestinal manifestations of the coronavirus disease 2019 (COVID-19)*.

Originating from Wuhan, China, the outbreak of coronavirus disease 2019 (COVID-19) pandemic has instigated major turmoil with its global impacts yet to be fully appreciated. The SARS-CoV-2, the causative agent of COVID-19, shares about 79% of its genetic sequence with the 2003 severe acute respiratory syndrome (SARS) coronavirus. With SARS or COVID-19, typical respiratory symptoms can be preceded by gastrointestinal symptoms including nausea, vomiting, diarrhea, and abdominal discomfort. Up to 60% of patients with SARS had been reported to show liver impairment, and mild-to-moderate liver injury has been reported in patients with COVID-19. Although the coronavirus notably causes a series of respiratory illnesses, the SARS-CoV-2 can also be detected in stool specimens, raising the possibility of gastrointestinal infection and fecal--oral transmission.

In this issue of *Gastroenterology* accompanied by a commentary by Gu et al, Xiao et al examined the gastrointestinal manifestations of COVID-19 among 73 hospitalized patients in China. The SARS-CoV-2 RNA was found in stool samples of 39 patients (53%). A total of 17 (23%) remained positive in stool RNA after testing negative in respiratory secretions. Duration of positive stool tests ranged from 1 to 12 days. In addition to viral RNA, SARS-CoV-2 had been isolated from stool samples, suggesting the release of infectious virions to the gastrointestinal tract. Angiotensin-converting enzyme 2 receptors, the presumptive entry points of SARS-CoV-2 to human cells, are highly expressed, not only in respiratory tract mucosa, but also in glandular gastrointestinal epithelial cells and cholangiocytes. Taken together, these results suggest that the digestive system could serve as an alternative route of infection and transmission for the SARS-CoV-2. Further characterization of the gastrointestinal manifestations may help in early detection and effective quarantine in our global efforts against the COVID-19 pandemic.

**See pages 1518 and 1831**.

Stratification of Barrett's Esophagus and Esophageal Adenocarcinoma by Multiomics Data {#sec3}
======================================================================================

*Multiomics approaches define 4 distinct Barrett's Esophagus and esophageal adenocarcinoma subtypes. Methylation status may stratify tumor response to chemotherapeutic modality*.

Esophageal adenocarcinoma (EAC) has a remarkably poor prognosis secondary to aggressive tumor characteristics and often being detected at an advanced stage of disease. Metaplastic changes frequently precede EAC, unlike esophageal squamous carcinoma, and are thought to be produced by chronic esophageal exposure to reflux components such as acid and bile. While mutational and genomic studies have identified mutations associated with both Barrett's esophagus (BE) and EAC, genome-wide methylation studies are lacking. In this issue of *Gastroenterology*, Jammula et al studied 150 BE, 285 EAC, and 100 normal controls from the Esophageal Cancer Classification and Molecular Stratifications Consortium in the United Kingdom. Methylation profiles were associated with whole-genome sequencing and RNA-seq analysis. Using this approach, they were able to assign BE and EAC samples into 1 of 4 subtypes: subtype 1, high mutation burden and DNA hypermethylation with cell cycle regulators and receptor tyrosine signaling being common mutational targets; subtype 2 consisted mainly of BE samples in which there was metabolic activation and relative DNA hypomethylation; subtype 3, with no difference in methylation with control samples, but with immunoinfiltration signature and overall poor survival' and subtype 4, DNA hypomethylation with predominant genomic instability, copy number alterations, and amplification of cyclin E ([Figure 2](#fig2){ref-type="fig"} ). TP53 and CDKN2A were the two most frequently altered genes across all subtypes. The methylation status of the MGMT promoter is directly associated with temozolomide chemosensitivity in glioblastoma multiforme. MGMT was heavily methylated in up to one-third of EAC cases and EAC organoids with low MGMT expression were most sensitive to temozolomide. Similarly, organoids with lower CHFR, a cell cycle checkpoint inhibitor, were sensitive to docetaxel. This large, multimodal genomics study helps to refine the BE and EAC landscape and provides important clues that will be helpful for prognostication and therapeutic targeting.Figure 2Overview of different biological features unique to individual subtypes.
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Resolution of Fibrosis via Stellate Cell Transcriptional Targeting {#sec4}
==================================================================

*Hepatic stellate cell phenotypes are defined by a complex interplay between several transcriptional regulatory networks. Targeting PPARγ signaling suppressed profibrogenic activity of human hepatic stellate cells in a mouse model of fibrosis*.

Hepatic injury responses, intended to initiate cellular programming designed to restore normal hepatic capabilities, can go awry resulting in prolonged and exaggerated restitution programs, activating hepatic stellate cells resulting in collagen production and hepatic fibrosis. The fibrogenic process is partially reversible when promoting factors are terminated and activated stellate cells are reprogramed from fibrogenic transcriptional profiles to quiescent. Critical signaling pathways controlling hepatic cell fate, such as those involved in fibrogenic processes, are not well-delineated. In this issue of *Gastroenterology*, Liu et al used a variety of liver specific knockout mouse models and human hepatic stellate cells (HSC) to explore HSC plasticity. Analyzing a combination of hepatic reporter lines, transcriptomic and ChIP-seq approaches they identified ETS1/2, GATA4/6, and IRF1/2 as HSC lineage defining transcription factors and shRNA-knockdown of ETS/GATA factors increased inflammatory and fibrinogenic gene transcription. They further determined that HSC specific deletion of the ETS1 target gene PPARγ worsened carbon-tetrachloride induced hepatic fibrosis. Similar to mouse, human HSCs demonstrated plasticity with resolution of the fibrogenic phenotype when transplanted into livers of *Rag2* ^*--/--*^ *;yc* ^*--/--*^ immunocompromised mice and treatment with rosiglitazone, a PPARγ agonist, suppressed activation of human HSCs, highlighting the prominent role of PPARγ signaling in the resolution of hepatic fibrogenic programs.
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